CJC-1295 NO DAC + Ipamorelin (10mg Blend)

Description

This profile combines CJC-1295 w/o DAC with ipamorelin, a dual secretagogue strategy studied for GH pulse behavior and downstream GH/IGF-1 signaling responses.

What it is

CJC-1295 w/o DAC + Ipamorelin is a dual secretagogue blend profile combining GHRH-pathway and ghrelin-axis signaling hypotheses in GH-axis research.

Mechanism snapshot

• Combines GHRH-receptor stimulation concepts from CJC-1295-class analog literature.
• Adds ghrelin-receptor agonism signaling from ipamorelin component studies.
• Investigated for GH pulse dynamics and downstream GH/IGF-1 biomarker responses.

Research programs

• Dual-agent secretagogue protocol design and timing analyses.
• Component-based endocrine response mapping in controlled settings.
• Comparative single-agent versus blend hypothesis testing.

Limitations

• Most CJC studies involve long-acting constructs rather than exact w/o DAC blend formulas.
• Component-level evidence does not automatically validate fixed-ratio blend effects.
• Clinical datasets are generally small and endpoint-limited.

Selected references

• Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults - PubMed 2006
• Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog - PubMed 2006
• Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers - PubMed 1999
• A Study to Evaluate CJC 1295 in HIV Patients With Visceral Obesity (NCT00267527) - ClinicalTrials.gov Status snapshot

Ordering

Add this item to your cart, submit your shipping details at checkout, and wait for your order confirmation. Interac e-Transfer instructions are sent after the order request is received.